The Early Career Steering Committee was set up with the aim of supporting and facilitating the ongoing career development of early career researchers within the MWC. The Committee's goal is to help EC researchers develop and succeed within the MWC through organising events and providing opportunities for EC researchers to get together, discuss their work and build collaborative networks across New Zealand.
Early Career Steering Committee
Dr Chris Guisec.email@example.com
Chris is a member of the Translational Therapeutics Team based at the Auckland Cancer Society Research Centre (ACSRC). His research focus is the development of new anti-cancer drugs that target features of the tumour microenvironment. It is well documented that cancers develop a poor blood supply which limits delivery of oxygen to the cancer environment. As such, regions of severe low oxygen are a common feature of cancer, whilst being absent in healthy tissue. These hypoxic cancer regions are strongly associated with disease progression, metastatic spread and resistance to treatment. One approach to eliminate these treatment-resistant cancer cells is the development of hypoxia-activated prodrugs. These prodrugs are designed to exhibit minimal toxicity in healthy tissues but become activated to potent anti-cancer drugs selectively within hypoxic tumour regions. His research has played a key role in helping to understand the mechanisms of action of two clinical stage prodrugs developed in the ACSRC, PR-104 and Tarloxotinib Bromide.
COMMITTEE CHAIR Dr Joanna Hicksjoanna.firstname.lastname@example.org
Joanna is a post-doctoral researcher in Professor Vic Arcus’ lab at the University of Waikato. She received her PhD in biochemistry and molecular biology in 2011. She then spent 3 years at the University of Cambridge in the Department of Biochemistry, researching transcription and post-transcriptional regulation in the remnant chloroplast of malaria. Her current research has two main themes, focusing on toxin-antitoxin systems and transcriptional regulation in pathoegnic bacteria and enzyme engineering and inhibitor design.